165,850 Shares in AbbVie Inc. $ABBV Bought by NFJ Investment Group LLC

NFJ Investment Group LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the second quarter, HoldingsChannel reports. The institutional investor purchased 165,850 shares of the company’s stock, valued at approximately $41,734,000. AbbVie comprises about 1.4% of NFJ Investment Group LLC’s holdings, making the stock its 18th biggest holding.

Several other large investors also recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of AbbVie during the fourth quarter worth about $5,865,055,000. Wellington Management Group LLP boosted its position in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Capital World Investors boosted its position in shares of AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Cardano Risk Management B.V. grew its stake in AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after buying an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after buying an additional 4,190,487 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ABBV. BMO Capital Markets boosted their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Royal Bank Of Canada upped their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $275.95.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for a subcutaneous induction regimen of Skyrizi in adults with moderately to severely active Crohn’s disease. The filing, supported by Phase 3 AFFIRM data, could broaden Skyrizi’s commercial opportunity and help offset longer-term concerns about AbbVie’s product portfolio. Is AbbVie Undervalued As It Expands Skyrizi In Crohns Disease?
• Positive Sentiment: Analysts remain broadly optimistic about ABBV’s outlook despite the stock’s reported underperformance versus healthcare peers over the past year. The aging population is also viewed as a long-term demand driver for AbbVie’s immunology treatments. How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. Investors may look for updates on Skyrizi, Rinvoq and the company’s earnings outlook, but no new financial information was provided in the announcement. AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Trading has been relatively steady as investors await the next earnings update. Recent results provide a supportive backdrop: AbbVie previously exceeded quarterly EPS and revenue expectations, with revenue up year over year. AbbVie Stock Holds Steady as Investors Await the Next Earnings Update
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate for AbbVie, creating a modest headwind for the stock and highlighting the risk that expectations may be difficult to exceed.
• Negative Sentiment: Recent institutional activity was mixed, with Burke & Herbert Bank & Trust selling shares while another manager initiated a position. These 13F changes are historical and have limited near-term significance, but the sale may add slight negative sentiment. Burke and Herbert Bank Sells AbbVie Shares

AbbVie Stock Up 0.6%

ABBV opened at $256.95 on Tuesday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The business has a 50 day moving average price of $253.20 and a two-hundred day moving average price of $229.16. The company has a market cap of $453.98 billion, a PE ratio of 72.58, a P/E/G ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.